We determined that Genedata Biologics was the best solution to fully address all our unique workflow requirements as it enables scale up of the screening, engineering, production and testing of complex multi-specific antibody candidates.”
SAN FRANCISCO (PRWEB) August 20, 2018
Genedata, a leading provider of advanced software solutions for biopharma R&D, today announced that Seattle-based Aptevo Therapeutics, a clinical-stage biotechnology company, has adopted Genedata as their preferred bioinformatics solution provider. Aptevo will use the Genedata Biologics® platform to facilitate expansion of their pipeline of novel bispecific antibody candidates focused on immuno-oncology, autoimmune disease and inflammation.
“To increase the throughput of our bispecific discovery program we needed a flexible E2E workflow system that could support our proprietary discovery technologies and ADAPTIR™ protein therapeutic platform,” said Dr. Peter Pavlik, Director of Molecular Biology and Protein Engineering Research at Aptevo. “We determined that Genedata Biologics was the best solution to fully address all our unique workflow requirements as it enables scale up of the screening, engineering, production and testing of complex multi-specific antibody candidates.”
“We appreciate Genedata Biologics’ flexible business model, which made it possible for a company of our size to adopt a market-leading platform solution,” said William Benjamin, IT Director at Aptevo. “As an established, off-the-shelf product, Genedata Biologics could be deployed across our organization with minimal customization. Also, this cloud-based solution was particularly appealing because of the rapid implementation it offered. We are very pleased with Genedata’s strong commitment to service and technical support and look forward to a long and productive partnership.”
“We are excited to work with Aptevo, an innovative leader in the development of novel immunotherapies. This partnership illustrates how Genedata works with future industry leaders who need a platform for scale up and automation of their R&D operations as they grow as an organization,” said Dr. Othmar Pfannes, CEO of Genedata. “We are committed to helping our partners – both large and small – be innovative and at the same time efficient.”
Since its first release in 2011, Genedata Biologics has been rapidly adopted by the majority of the world’s leading biopharmaceutical companies, as well as emerging specialty biotech companies. Genedata’s collaborations range from single group installations to large, global, multi-site partnerships and include technology transfer, customizations, project management, training, and roll out and deployment support.
On August 21 at 11:20 EDT, Genedata Biologics will be featured at the Bispecific Antibody Pipeline Congress in the presentation “Bispecific Platform Designed for Rapid Development and Manufacturing of Novel Protein Therapeutics” by Peter Pavlik, PhD, Principle Scientist, Aptevo Therapeutics.
To schedule a briefing, contact firstname.lastname@example.org.
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.
Follow Us on LinkedIn
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.